Company Overview
Snapshot
Founded in August 2012 by Dekel Taliaz and Oren Taliaz, Taliaz operates with 11–50 employees. The company has secured $3.2 million in total capital across two funding rounds. In October 2022, Taliaz announced a collaboration with Cerba to leverage AI and genetics expertise for improving patient care management in depression.
Business overview
Taliaz develops Predictix, an AI-based platform designed to assist doctors in delivering personalized medicine, primarily focusing on mental health. Its flagship application, Predictix Anti-Depressant AI, analyzes genomic, clinical, and demographic data to generate personalized reports on antidepressant efficacy and side effects. This decision-support tool helps general practitioners and specialists optimize treatment strategies for improved patient outcomes. The company operates within the Health Tech & Life Sciences sector, specifically targeting digital healthcare and medical decision support, and serves markets in the EU and Israel.
Strategic signal
In October 2022, Taliaz partnered with Cerba to combine their expertise in artificial intelligence and genetics to enhance patient care management for depression. This collaboration signals a strategic move to integrate advanced AI-driven diagnostic capabilities with genetic insights, aiming to provide more precise and effective treatment pathways for mental health patients. For investors, this indicates a validation of Taliaz's technology through a significant partnership, potentially expanding its market reach and reinforcing its position in personalized mental health solutions.
Log in to access full profile ›Company Intelligence Q&A
- What was the most recent significant partnership for Taliaz?
- In October 2022, Taliaz announced a partnership with Cerba to combine artificial intelligence and genetics expertise to improve patient care management in depression.
- When did Taliaz achieve CE Certification for its PREDICTIX Digital solution?
- In December 2020, Taliaz completed CE Certification for its PREDICTIX Digital AI mental health solution, enabling its expansion into European healthcare and telehealth markets.
- Did Taliaz receive any grants to support its mental health platform?
- In November 2020, Taliaz was awarded a $2.7 million grant from the European Union's Horizon 2020 program to support further clinical research and development of its PREDICTIX mental health platform.
- When did Taliaz launch its online service with Psychiatry UK?
- In April 2019, Taliaz partnered with Psychiatry UK to launch Predictix, an online service utilizing AI-driven genetic testing to help identify appropriate antidepressant medication for depression sufferers.
- What was the initial investment amount Taliaz raised?
- In July 2018, Taliaz had raised approximately $1.3 million to date for its platform that uses AI and machine learning to create personalized drug treatments.